368426-73-7

Usage

Uses

Used in Pharmaceutical Research and Development:
4-(Aminomethyl)-2-fluorobenzonitrile is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure, which includes a fluorine atom and an aminomethyl group, allows it to be a building block for creating new drug molecules with specific therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, 4-(Aminomethyl)-2-fluorobenzonitrile is employed as a versatile intermediate for the development of new agrochemicals. Its ability to be modified and incorporated into complex molecules makes it suitable for the creation of pesticides, herbicides, and other agricultural chemicals that can improve crop yields and protect plants from pests.
Used in Organic Synthesis:
4-(Aminomethyl)-2-fluorobenzonitrile serves as a valuable intermediate in organic synthesis, where it can be used to construct a wide range of organic compounds. Its reactivity and functional groups make it a useful component in the synthesis of specialty chemicals, materials, and other organic compounds for various applications.
Used in Medicinal Chemistry:
Due to its potential biological activity and medicinal properties, 4-(Aminomethyl)-2-fluorobenzonitrile is studied and used in medicinal chemistry for the design and development of new therapeutic agents. Its structural features can be exploited to create molecules with specific binding affinities and pharmacological effects, contributing to the advancement of medicine.

InChI:InChI=1/C8H7FN2/c9-8-3-6(4-10)1-2-7(8)5-11/h1-3H,4,10H2

Upstream product

• 368426-72-6 4-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-2-fluoro-benzonitrile 
• 452-74-4 4-bromo-3-fluorotoluene 
• 85070-67-3 2-fluoro-4-methylbenzonitrile 
• 222978-03-2 4-cyano-3-fluorobenzylbromide 
• 368426-76-0 4-azidomethyl-2-fluorobenzonitrile 

Downstream Products

• 229623-55-6 4-(tert-butoxycarbonylaminomethyl)-2-fluorobenzonitrile 
• 368426-77-1 tert-butyl ((3-aminobenzo[d]isoxazol-6-yl)methyl)carbamate 
• 1456615-87-4 C₁₃H₁₈FN₃O₃ 
• 433939-85-6 Boc-Aze-NHCH₂-Ph(3-F, 4-CN) 

Relevant academic research and scientific papers

Optimization of Novel 1-Methyl-1 H-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber's Pole Worm

A phenotypic screen of a diverse library of small molecules for inhibition of the development of larvae of the parasitic nematode Haemonchus contortus led to the identification of a 1-methyl-1H-pyrazole-5-carboxamide derivative with an IC50 of 0.29 μM. Medicinal chemistry optimization targeted modifications on the left-hand side (LHS), middle section, and right-hand side (RHS) of the scaffold in order to elucidate the structure-activity relationship (SAR). Strong SAR allowed for the iterative and directed assembly of a focus set of 64 analogues, from which compound 60 was identified as the most potent compound, inhibiting the development of the fourth larval (L4) stage with an IC50 of 0.01 μM. In contrast, only 18% inhibition of the mammary epithelial cell line MCF10A viability was observed, even at concentrations as high as 50 μM.

Mandelic acid derivatives and their use as throbin inhibitors

There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.

Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-bicyclic arginine surrogates

Novel, potent, and highly selective classes of thrombin inhibitors were identified, which resulted from judicious combination of P4-aromatics and P2-P3-heterocyclic dipeptide surrogates with weakly basic (calcd pKa ～non-basic - 8.6) bicyclic P1-arginine mimics. The design, synthesis, and biological activity of achiral, non-covalent, orally bioavailable inhibitors NC1-NC44 featuring P1-indazoles, benzimidazoles, indoles, benzotriazoles, and aminobenzisoxazoles is disclosed.